Trial Profile
Phase II Study of Paclitaxel With Imatinib Mesylate (Gleevec) in Taxane-pretreated Ovarian and Other Cancers of Mullerian Origin.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Paclitaxel (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 16 Nov 2012 Actual end date (Oct 2012) added as reported by ClinicalTrials.gov.
- 05 Oct 2012 Planned end date changed from 1 Apr 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 01 Oct 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.